Work

110P: Prediction of the individual risk for the development of brain metastases in patients with stage IV NSCLC without actionable genomic alterations: Data from the German CRISP registry (AIO-TRK-0315)

Year: 2025

Type: article

Study design: Observational Study

Source: Journal of Thoracic Oncology

DOI: 10.1016/s1556-0864(25)00305-3

Authors: F. Acker, K. Wenger, M. Reck, C. Waller, P. Hoffknecht, A. Bethge, M. Jaenicke, A. Fleitz, C. Lennartz, P. Ludwig, A. Groth, A. Nusch, M. Reiser, M. Ludwig, M. Bendel, F. Griesinger, M. Thomas, W.E.E. Eberhardt, M. Sebastian

Institutions: Goethe University Frankfurt, University Hospital Frankfurt, German Center for Lung Research, LungenClinic Grosshansdorf, University Medical Center Freiburg, Iomedico (Germany), AIO Studien gGmbH, Medizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer, Pius Hospital Oldenburg

Language: English

Topic: Brain Metastases and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Celgene, Regeneron Pharmaceuticals, Les Laboratories Pierre Fabre, Mylan, BeiGene, Revolution Medicines, Seagen, Ipsen, Chugai Pharmaceutical, Daiichi Sankyo Europe

OpenAlex ID: W4408979495

FWCI:

Cites:

Cited by:

Related to: 10